{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-23-000106","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2023-06-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.385220+00:00","generated_at":"2026-06-13T15:45:17.771770+00:00","sec_items":["7.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Founder and CSO Steven Prestrelski resigns, becomes Senior Scientific Advisor at Xeris Biopharma","bullets":["Steven Prestrelski, PhD, Founder and Chief Scientific Officer, resigned effective June 30, 2023.","He entered a consulting agreement as Senior Scientific Advisor from July 1, 2023 to January 31, 2025.","The consulting agreement covers predefined services; no further financial terms disclosed.","Transition follows founder's departure from executive role but retention as advisor."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-23-000106","json":"https://secwatch.observer/filing/0001867096-23-000106.json","markdown":"https://secwatch.observer/filing/0001867096-23-000106.md","text":"https://secwatch.observer/filing/0001867096-23-000106.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000106/0001867096-23-000106-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000106/xers-20230628.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T15:45:17.771770+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}